PATIENT
RESOURCES
ARELYSMother, avid traveler, and actual Oxbryta patient
YOU HAVE SUPPORT ON YOUR JOURNEY WITH SICKLE CELL
There are resources and helpful materials available to guide and support you or the person you care for throughout the entire journey.
GBT SOURCE SOLUTIONS®
We all need a little help sometimes. Oxbryta comes with support from GBT Source, our Patient Support Program. At GBT Source, we believe that you or your child’s journey with Oxbryta should be as seamless as possible. GBT Source will support with assistance paying for treatment (for qualifying patients), receiving treatment, and staying on treatment as prescribed.
Care Coordinators will:
- Help those enrolled understand their insurance benefits
- Review and provide information on financial assistance programs based on eligibility
Access Navigators will:
- Contact those who opted in on the Patient Authorization and Consent Form to schedule an introductory session that will give more information about the support provided by GBT Source throughout the treatment journey
A Nurse Support Team is available to:
- Answer questions about Oxbryta, including how to take it
- Provide resources and personalized support to help patients start and stay on treatment as prescribed by their healthcare provider*
Your Speciality Pharmacy will:
- Reach out to coordinate delivery of Oxbryta
- Follow up to make sure it’s delivered
- Get Oxbryta refills authorized as needed
- Answer any questions anytime (pharmacist available by phone 24/7)
The Nurse Support Team is there to support product adherence and not replace a patient’s treatment plan. They do not provide medical advice or care management services.
To learn more, call
(833) 428-4968
PRESS OPTION 1 TO SPEAK WITH A REPRESENTATIVE
(833-GBT-4YOU) M-F, 8am-8pm ET
Get support for Oxbryta from day one. Learn more about GBT Source now.
GBTSOURCE.COM
DOWNLOAD RESOURCES
GBT Source Patient Brochure
Information about Oxbryta treatment support and how to get started with GBT Source.
DOWNLOAD
FOR ORAL SUSPENSION
Oxbryta 300 mg Tablets for Oral Suspension Dosing Card
Information about dosing and taking Oxbryta 300 mg Tablets for Oral Suspension.
DOWNLOAD
Oxbryta 500 mg Tablets Dosing Card
Information about dosing and taking Oxbryta 500 mg Tablets.
DOWNLOAD
Oxbryta Patient Brochure
Learn more about sickle cell and treatment with Oxbryta, and find specific questions you can ask your healthcare provider to get the conversation started.
DOWNLOADFIND EDUCATION AND SUPPORT
Find Patient Events
Search for virtual or local educational events to learn from a specialist about sickle cell and how Oxbryta treats sickling at its source.
SEARCH NOW
Find Support Organizations
Search community-based and national organizations offering support and resources that may be available in your area. These organizations are independent and not affiliated with GBT Source.*
These resources are meant to be informational only and are not intended to replace medical advice.
SEARCH NOWWhat do real people taking Oxbryta have to say?
PATIENT STORIES
INDICATION
What is OXBRYTA?
OXBRYTA is a prescription medicine used for the treatment of sickle cell disease in adults and children 4 years of age and older.
It is not known if OXBRYTA is safe and effective in children with sickle cell disease below 4 years of age.
This indication is approved under accelerated approval based on increase in hemoglobin (Hb). Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).
IMPORTANT SAFETY INFORMATION
Do not take OXBRYTA if you or your child have had an allergic reaction to voxelotor or any of the ingredients in OXBRYTA. See the end of the patient leaflet for a list of the ingredients in OXBRYTA.
Before taking OXBRYTA, tell your healthcare provider about all of your medical conditions, including if you or your child:
- have liver problems
- are pregnant or plan to become pregnant. It is not known if OXBRYTA can harm your unborn baby.
- are breastfeeding or plan to breastfeed. It is not known if OXBRYTA can pass into your breastmilk and if it can harm your baby. Do not breastfeed during treatment with OXBRYTA and for at least 2 weeks after the last dose.
Tell your healthcare provider about all the medicines you or your child take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Some medicines may affect how OXBRYTA works. OXBRYTA may also affect how other medicines work and may affect the results of certain blood tests. Keep a list of all your medicines and show it to your healthcare provider.
What should I avoid while taking OXBRYTA?
Do not take St. John’s wort during treatment with OXBRYTA.
What are the possible side effects of OXBRYTA?
OXBRYTA can cause serious side effects, including:
Serious allergic reactions. Tell your healthcare provider or get emergency medical help right away if you get:
- rash
- hives
- shortness of breath (difficult breathing)
- swelling of the face
The most common side effects of OXBRYTA include:
- headache
- diarrhea
- stomach-area (abdominal) pain
- nausea
- rash or hives
- fever
The most common side effects of OXBRYTA in children ages 4 to less than 12 years of age include:
- fever
- vomiting
- rash
- stomach-area (abdominal) pain
- diarrhea
- headache
These are not all the possible side effects of OXBRYTA.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. You may also report side effects to Global Blood Therapeutics at 1-833-428-4968 (1-833-GBT-4YOU).
Keep OXBRYTA and all medicines out of the reach of children.
Oxbryta, GBT Source, GBT Source Solutions, and the GBT logo are registered trademarks of Global Blood Therapeutics, Inc. All other trademarks are the property of their respective owners.
© 2022 Global Blood Therapeutics, Inc. All Rights Reserved. P-VOX-US-00098 v8
This site is intended for residents of the United States, Puerto Rico, and US territories.
MORE Back to top
Stay in the know
Receive additional information on Oxbryta and sickle cell.
© Global Blood Therapeutics, Inc.